Erythropoietic protoporphyria (EPP) is a rare genetic condition in which a buildup of a light-sensitive molecule called protoporphyrin IX in red blood cells causes severe, burning pain within minutes of sun exposure. Unlike a sunburn, the pain typically leaves no visible mark on the skin, which is one reason the condition is so frequently missed or dismissed. EPP usually begins in early childhood and persists for life, affecting not just the skin but potentially the liver and overall quality of life in ways that demand ongoing medical attention.
What Happens in the Body
The root problem in EPP is a partial shortage of an enzyme called ferrochelatase, which sits at the final step of the body’s process for making heme, the iron-containing component of hemoglobin. When ferrochelatase activity drops below a critical threshold, its substrate, protoporphyrin IX, accumulates in developing red blood cells and spills into the bloodstream and skin. Protoporphyrin IX absorbs light, particularly in the blue-violet and visible range around 400 to 410 nanometers. When it does, it generates reactive oxygen species that damage tiny blood vessels and nerve endings in the skin, producing an intense burning and stinging sensation that can last for hours or even days after exposure.
1PubMed Central. Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and managementThe body clears excess protoporphyrin mainly through the liver and bile rather than through the kidneys. This hepatic route of elimination is why liver damage is the most serious long-term risk of the disease, as we’ll see below.
2PubMed Central. Liver disease and erythropoietic protoporphyria: a concise reviewHow Symptoms Show Up and Why Doctors Miss Them
EPP almost always starts in early childhood, often as soon as a toddler begins spending time outdoors. The hallmark symptom is acute, sometimes excruciating pain in sun-exposed skin, especially the face, hands, and tops of the feet. Children may cry, scream, or try to hide from sunlight without being able to explain why. Older children and adults describe the sensation as burning, tingling, or stinging rather than itching. Swelling and redness can occur but are often subtle and short-lived, and many patients show no visible skin changes at all during an episode.
3PubMed Central. Diagnostic Delay in Erythropoietic ProtoporphyriaThis mismatch between invisible symptoms and visible skin is the central reason for diagnostic delay. Because there is often nothing to see, clinicians may attribute the complaints to anxiety, behavioral issues, or sun allergy. Children who refuse to go outside for recess or who plunge their hands into cold water after being in the car get labeled as difficult or overdramatic. The lack of blisters sets EPP apart from other porphyrias like porphyria cutanea tarda, where the skin damage is obvious. EPP is considered the second most common porphyria seen in clinical practice, yet it remains widely under-recognized.
4PubMed Central. The diagnosis and management of erythropoietic protoporphyriaThe Genetics Behind EPP
EPP is sometimes called autosomal dominant, but the reality is more nuanced. Most people who develop symptoms carry two genetic hits on the ferrochelatase gene (FECH), not just one. On one copy of the gene, they inherit a clearly damaging mutation, often unique to their family. On the other copy, they inherit a common variant deep inside the gene, known as IVS3-48C, that causes a subtle splicing error. This variant makes the cell produce a slightly lower-than-normal amount of functional ferrochelatase from that gene copy. By itself, the IVS3-48C variant does not cause disease. But when it sits opposite a loss-of-function mutation on the other chromosome, total enzyme activity drops below the threshold needed to keep protoporphyrin from piling up.
5PubMed Central. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECHThis two-hit model explains a pattern that puzzles many families: not everyone who carries the FECH mutation gets sick. A parent with the mutation may pass it to two children, but only the child who also inherits the IVS3-48C variant on the other chromosome develops symptoms. The other child, who got the normal-splicing version, has enough residual enzyme activity to stay below the danger zone. Studies of affected families confirm this: clinically affected members carry both the mutation and the hypomorphic allele, while clinically silent carriers have the mutation but not the low-expression variant.
6PubMed. A Novel Mutation in the FECH Gene in a Czech Family with Erythropoietic Protoporphyria and a Population Study of IVS3-48C Variant Contributing to the DiseaseThe frequency of the IVS3-48C variant varies by ethnicity, which helps explain why EPP prevalence differs across populations. In some European populations, roughly one in ten people carry this variant, while in East Asian populations the frequency is lower. Because both the rare mutation and the common variant are required, genetic counseling can be surprisingly complex.
X-Linked Protoporphyria, the Close Relative
A condition that looks nearly identical to EPP on the surface, X-linked protoporphyria (XLP), was only formally recognized in 2008. Instead of a deficiency in ferrochelatase, XLP results from gain-of-function mutations in a different gene, ALAS2, which encodes the first and rate-limiting enzyme in heme production specifically in red blood cell precursors. These mutations cause ALAS2 to become hyperactive, flooding the pathway with far more substrate than ferrochelatase can handle, and protoporphyrin IX accumulates as a result.
7American Journal of Human Genetics. C-Terminal Deletions in the ALAS2 Gene Lead to Gain of Function and Cause X-Linked Dominant Protoporphyria without Anemia or Iron OverloadBecause ALAS2 sits on the X chromosome, the inheritance pattern differs. Males need only one mutant copy to be affected. Females can also develop symptoms since the mutations are dominant, though severity may vary depending on which X chromosome is preferentially active in their red blood cell precursors. The day-to-day experience for patients with XLP is essentially the same painful photosensitivity as in EPP, but XLP tends to carry a higher risk of liver complications and shows a distinctive biochemical signature: a larger proportion of zinc-protoporphyrin in the blood alongside the metal-free form.
8PubMed Central. Molecular expression and characterization of erythroid-specific 5-aminolevulinate synthase gain-of-function mutations causing X-linked protoporphyriaA third, even rarer variant, called CLPX-protoporphyria, has also been identified. All three conditions, EPP, XLP, and CLPX-protoporphyria, cause the same downstream problem: too much protoporphyrin IX in red blood cells.
9PubMed Central. Erythropoietic protoporphyrias: Pathogenesis, diagnosis and managementGetting the Right Blood Test
A diagnosis of EPP rests on a specific blood test: total erythrocyte protoporphyrin. In people with EPP, this value is markedly elevated, typically ranging from about 300 to 5,000 micrograms per deciliter of red blood cells, compared with a normal reference below 80. Crucially, the protoporphyrin in EPP is predominantly metal-free, accounting for 85 to 100 percent of the total. In conditions like iron deficiency or lead poisoning, protoporphyrin also rises, but it is mostly the zinc-bound form. This distinction is what separates EPP from other causes of elevated erythrocyte protoporphyrin.
10PubMed Central. Pitfalls in Erythrocyte Protoporphyrin Measurement for Diagnosis and Monitoring of ProtoporphyriasOne practical pitfall: plasma porphyrin levels are not always elevated in EPP, so testing only plasma can miss the diagnosis entirely. The test needs to be done on washed red blood cells with a method that can distinguish metal-free from zinc-protoporphyrin. If the ratio tips toward a higher proportion of zinc-protoporphyrin, that points toward XLP rather than classic EPP, which then informs genetic testing decisions. Getting the right lab assay matters, and not all commercial labs run it correctly.
The Liver Risk
Photosensitivity dominates daily life, but liver disease is the most medically dangerous complication of EPP. The liver bears the burden of clearing protoporphyrin from the body, and when protoporphyrin accumulates in liver cells and bile ducts, it triggers cholestasis, oxidative stress, and progressive damage. The spectrum ranges from gallstones (protoporphyrin-rich stones are common) to mild chronic liver injury to, in a small but devastating minority, acute liver failure requiring emergency transplantation.
11PubMed Central. Liver disease and erythropoietic protoporphyria: a concise reviewBecause liver failure can develop rapidly and unpredictably, consensus guidelines stress the importance of regular liver monitoring for all EPP patients, including periodic blood tests for liver function and protoporphyrin levels. Iron status and vitamin D levels should also be tracked, since both are commonly abnormal in this population.
12PubMed Central. Evidence-based consensus guidelines for the diagnosis and management of erythropoietic protoporphyria and X-linked protoporphyriaSunscreen Does Not Work the Way You Expect
One of the most frustrating aspects of EPP for patients is that conventional sunscreens offer little to no protection. Standard UV-blocking sunscreens are designed to filter ultraviolet radiation (below 400 nanometers), but the protoporphyrin IX molecule absorbs most strongly in the visible light range, particularly blue-violet light. Window glass blocks UV but transmits visible light, which is why people with EPP can experience pain while riding in a car or sitting near a window.
Testing of various sunscreen products showed that most commercial formulas transmitted 75 to 95 percent of light at 500 nanometers, offering essentially no meaningful protection in the range that triggers EPP reactions. The best-performing product in one laboratory evaluation, a sunscreen containing titanium dioxide plus synthetic iron oxides (pigment-grade particles designed to absorb visible light), achieved a porphyrin protection factor of only about 4. Products relying on micronized inorganic filters performed even worse in the visible spectrum.
13PubMed Central. In vitro Assessment of Solar Filters for Erythropoietic Protoporphyria in the Action Spectrum of Protoporphyrin IXIn practice, physical barriers remain more effective than any topical product. Long sleeves, wide-brimmed hats, gloves, and UV-plus-visible-light window films for cars and homes are the mainstays. Some patients use tinted or opaque formulations meant to block visible light, but these are cosmetically thick and socially conspicuous, which adds to the psychosocial burden.
Afamelanotide, the First Targeted Treatment
For decades, the only real advice doctors could offer EPP patients was to avoid sunlight. That changed with afamelanotide, a synthetic analog of a natural hormone that stimulates melanin production. Administered as a slow-release implant under the skin roughly every two months, afamelanotide increases melanin density in the skin, providing a degree of protection against visible-light-induced damage.
In pivotal randomized trials, patients receiving afamelanotide spent significantly more pain-free time in sunlight compared with those on placebo. In the U.S. trial, the afamelanotide group had a median of about 69 hours of pain-free sun exposure over six months, compared with roughly 41 hours for placebo. A European trial over nine months found that patients on afamelanotide had fewer phototoxic reactions (77 vs. 146) and improved quality of life.
14PubMed Central. Afamelanotide for Erythropoietic ProtoporphyriaReal-world follow-up data paint a consistent picture. Patients treated with afamelanotide in clinical practice spent an average of six additional hours per week outdoors compared with their baseline, and quality-of-life scores improved by about 14 percent. Phototoxic reactions still occurred but were less painful.
15PubMed Central. Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical PracticeAfamelanotide is not a cure. It does not lower protoporphyrin levels or fix the underlying enzyme deficiency; it simply makes the skin somewhat more resilient to the light that triggers reactions. Patients still need to exercise caution, and the implant is not available in all countries.
Bitopertin and the Next Wave of Treatments
Where afamelanotide works downstream by shielding the skin, bitopertin targets the disease closer to its source. Bitopertin is a glycine transporter inhibitor, an oral medication originally developed for schizophrenia that was repurposed when researchers realized it could reduce the production of heme precursors in red blood cell progenitors. By limiting the availability of glycine, an amino acid needed for the first step of heme synthesis, bitopertin reduces how much protoporphyrin IX the body makes in the first place.
Results from the randomized, placebo-controlled AURORA trial showed that bitopertin meaningfully lowered protoporphyrin levels in the blood. At the higher dose, protoporphyrin dropped by about 50 percent compared with placebo, and phototoxic reactions decreased.
16PubMed. Bitopertin shows efficacy in patients with erythropoietic protoporphyria: Results from the randomized, double-blind, placebo-controlled AURORA trialAn earlier open-label study found that bitopertin was well tolerated in both adults and adolescents with EPP or XLP, a particularly important finding given that no approved therapies currently exist specifically for younger patients.
17Clinical and Experimental Dermatology. An open-label phase II study of bitopertin in adults and adolescents with erythropoietic protoporphyria or X-linked protoporphyriaIf bitopertin gains regulatory approval, it would be the first disease-modifying oral treatment for EPP, one that actually reduces the toxic molecule rather than merely increasing skin tolerance. That distinction matters for liver protection as well, since lower circulating protoporphyrin means less being dumped into the bile.
When the Liver Fails, Transplantation Gets Complicated
For the small percentage of EPP patients who develop end-stage liver disease, liver transplantation is lifesaving but not curative. Because the bone marrow, not the liver, is the source of excess protoporphyrin, a transplanted liver immediately begins accumulating the same damaging molecule. Recurrence of EPP-related liver injury in the graft has been documented repeatedly.
18American Journal of Transplantation. Sequential liver and hematopoietic stem cell transplantation for severe erythropoietic protoporphyria in an adultThe only way to correct the underlying defect is to replace the bone marrow itself through hematopoietic stem cell transplantation. Case reports describe a sequential approach: liver transplant first to address the immediate organ failure, followed by bone marrow transplant to stop protoporphyrin overproduction at its source. This strategy has been reported successfully in both pediatric and adult patients. In one case, a 13-year-old who had developed cirrhosis and respiratory complications received a liver transplant followed by a bone marrow transplant from an unrelated donor. Her protoporphyrin levels normalized, and she remained in good health nearly a year later.
19PubMed. Consecutive Liver and Bone Marrow Transplantation for Erythropoietic Protoporphyria: Case Report and Literature ReviewThese procedures carry significant risks, including graft-versus-host disease and the toxicities of the preparative chemotherapy. They remain reserved for the most severe cases. The first reported successful sequential transplant for EPP demonstrated that the combination could resolve both the photosensitivity and the liver graft injury, but the approach is far from routine.
20Pediatrics. Sequential Liver and Bone Marrow Transplantation for Treatment of Erythropoietic ProtoporphyriaThe Hidden Burden on Daily Life
Numbers from clinical trials only capture part of living with EPP. A Dutch study of EPP patients found that social functioning scores were substantially lower than the general population, and patients had lower employment rates despite having attained higher-than-average education levels. Over a quarter of patients met criteria for Type-D personality, a pattern characterized by social inhibition and negative emotions. Treatment with afamelanotide improved social inhibition scores and social functioning, suggesting that the psychosocial damage is at least partly reversible when the underlying light sensitivity eases.
21PubMed. Erythropoietic protoporphyria in the Netherlands: Clinical features, psychosocial impact and the effect of afamelanotideThe isolation begins young. Children with EPP learn to avoid playgrounds, swimming pools, and outdoor birthday parties. Adolescents may withdraw from social activities that take place in sunlight, creating patterns of avoidance that persist into adulthood. The invisibility of the condition compounds the problem: teachers, coaches, and even family members may not believe the child is in genuine pain when the skin looks normal.
Vitamin D Deficiency and Bone Health
People who must avoid sunlight inevitably run short of vitamin D, and EPP patients are no exception. A study measuring vitamin D and bone density in EPP patients found that the majority were either deficient or insufficient, with a median vitamin D level that fell squarely in the deficient range. Both male and female patients showed bone density values in the osteopenia range at the spine, and women showed similar reductions at the hip.
22PubMed. Bone mineral density and vitamin D levels in erythropoietic protoporphyriaThis makes vitamin D supplementation and bone density monitoring a practical necessity for anyone with EPP, and consensus guidelines now include both as part of routine care.
23PubMed Central. Evidence-based consensus guidelines for the diagnosis and management of erythropoietic protoporphyria and X-linked protoporphyriaPregnancy and Symptom Fluctuation
An observation that has intrigued researchers is that some women with EPP report improvement in their photosensitivity during pregnancy. In one documented case, a woman experienced marked symptom relief during both of her pregnancies, with protoporphyrin levels in her blood dropping by more than half compared with pre-pregnancy and post-lactation measurements.
24PubMed. Erythropoietic protoporphyria improving during pregnancyThe likely explanation involves the expanded blood volume during pregnancy, which dilutes protoporphyrin concentrations, combined with changes in iron metabolism and red blood cell turnover. This is not universal, and the improvement reverses after delivery, but it offers a window into how dynamic the disease’s biochemistry can be. It also provides a clue that interventions reducing circulating protoporphyrin, like bitopertin, could translate into real symptom relief.